Find and Pitch Jounalists, Get Your Story Covered

Tags: statins statin lipid statin therapy kidney disease

	Profile	Recent Articles on Subject
1	Kristen Monaco MedPage Today	SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease - 18 days ago FDA Approves First-Ever Drug for Serious Liver Condition - 12 months ago
2	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: Ionis blazed trails in genetic medicine. On the cusp of a major approval, can it also be a commercial success? - 3 months ago
3	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Ionis blazed trails in genetic medicine. On the cusp of a major approval, can it also be a commercial success? - 3 months ago STAT+: How a tweet about a gene discovered long ago led to a $190 million startup and, maybe, hope for heart disease - 9 months ago
4	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about unsupported drug price hikes, an annual HIV prevention shot, and more - 3 months ago STAT+: Pharmalittle: We’re reading about menopause treatments, Novo plans for Wegovy in India, and more - 3 months ago STAT+: Pharmalittle: We’re reading about a key Merck drug trial, cheap Wegovy in China, and more - 3 months ago STAT+: Pharmalittle: We’re reading about a Merck drug-label controversy, Astellas pulling an application, and more - 4 months ago STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more - 6 months ago STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more - 8 months ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - about 1 year ago STAT+: Pharmalittle: Wegovy cuts heart attack risk in milestone trial; AstraZeneca prioritizes U.S. for RSV drug amid surge - over 1 year ago STAT+: Pharmalittle: Panel tells FDA that CRISPR sickle cell therapy is safe enough for patients; U.K. is urged to scrap IP demands in trade talks with India - over 1 year ago STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell - over 1 year ago
5	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Novel Therapy Reduced Liver Fat, Improved Fibrosis in MASH - 3 months ago Novel MASH Drug Reduces Liver Fat in Mid-Stage Trial - over 1 year ago
6	Nicole Lou MedPage Today Medical reporter @medpagetoday. Bird advocate. undisclosed remote location medical reporting	More Lp(a)-Reducing Tx; Cardiac Denervation for Afib; LAA Occluders at 5 Years - 3 months ago Beta-Blockers Fail to Deliver Secondary Prevention Benefit in Key MI Patients - 11 months ago ACC Meeting to Make Noise on Beta-Blockers, SGLT2i, Chelation Therapy for Acute MI - 11 months ago Statins and CKD; Farxiga's Limited Symptom Improvement; Stop Wasted TNKase - about 1 year ago Alleged Stroke Trial Misconduct; Ultrasound Tx for Severe AS; Farxiga's eGFR Drops - over 1 year ago Statins Reach More Patients With Pharmacist's Orders - over 1 year ago Novel PCSK9 Inhibitor Recaticimab Lowers Lipids With Less Frequent Shots - over 1 year ago Promising Debut for CRISPR Gene Editing Therapy for LDL Lowering - over 1 year ago Angioplasty Redeemed for Stable Angina in Sham-Controlled ORBITA-2 - over 1 year ago Highly Potent Statin Stands Out for Diabetes, Cataract Risks - over 1 year ago FXI Inhibitor Cuts Bleeds in Afib; COAPT Extends to Real World; AI Stroke Triage - over 1 year ago
7	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: With new Wegovy data in hand, Novo Nordisk will file for approval in MASH - 4 months ago STAT+: Alnylam’s twice-a-year drug lowered blood pressure when combined with common pills - 11 months ago STAT+: Positive trial results set up obesity drug Wegovy for use against heart failure - 11 months ago STAT+: Merck drug for rare cardiovascular condition approved in U.S. - 11 months ago STAT+: Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label - 12 months ago STAT+: Wegovy may have another helpful trick: fighting inflammation via the brain, study finds - about 1 year ago STAT+: Even as Wegovy rides high, interest surges in weight loss drugs that preserve muscle - over 1 year ago STAT+: Anthos stroke drug appears safer than common blood thinner in mid-stage trial - over 1 year ago
8	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Study on Sarepta Therapeutics’ Duchenne therapy diverges from the company line - 4 months ago STAT+: Madrigal wins first U.S. approval for drug to treat liver disease MASH - 12 months ago STAT+: First medicine developed to treat MASH expected to be approved soon - 12 months ago STAT+: KalVista pill reduces swelling symptoms caused by genetic disease, achieving goal of late-stage study - about 1 year ago STAT+: In first test for base editing, Verve’s one-time treatment lowers cholesterol levels in patients - over 1 year ago STAT+: Astellas shows enough data for eye treatment to support expanded use, but still lags competitor - over 1 year ago
9	Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. PoliticsStorytellingCats	FDA Grants Breakthrough Therapy Designation to Plozasiran for Familial Chylomicronemia Syndrome - 6 months ago
10	Randy Dotinga MedPage Today Indie scribbler, advocate. Board member, @ahcj. San Diego WritingAdvocacy	Statin Use Linked to Higher Risk of Glaucoma - 7 months ago

Journalists covering statin therapy